[go: up one dir, main page]

PE20020339A1 - PYRROLIDIN DERIVATIVES AS INHIBITORS OF METALOPROTEASES - Google Patents

PYRROLIDIN DERIVATIVES AS INHIBITORS OF METALOPROTEASES

Info

Publication number
PE20020339A1
PE20020339A1 PE2001000710A PE2001000710A PE20020339A1 PE 20020339 A1 PE20020339 A1 PE 20020339A1 PE 2001000710 A PE2001000710 A PE 2001000710A PE 2001000710 A PE2001000710 A PE 2001000710A PE 20020339 A1 PE20020339 A1 PE 20020339A1
Authority
PE
Peru
Prior art keywords
alkyl
pyrrolidin
hydrazide
mercapto
cycloalkyl
Prior art date
Application number
PE2001000710A
Other languages
Spanish (es)
Inventor
Johannes Aebi
Henrietta Dehmlow
Eric Argirios Kitas
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20020339A1 publication Critical patent/PE20020339A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE PIRROLIDIN DE FORMULA I DONDE R1 ES H, ALQUILCARBONILO, ARILCARBONILO; R2 ES ALQUILO, ALQUILCICLOALQUILO, ALQUILCICLOALQUILAQUILO, CICLOALQUILO, HALOALQUILO, ENTRE OTROS; R3 ES H, ARILO, ALQUILO, ARILSULFONILO, ENTRE OTROS; R4 ES H, ARILALQUILO, ALQUILO, ARILO, CICLOALQUILO, ENTRE OTROS; R5 ES H, ALQUILSULFONILO, ARILSULFONILO, HETEROARILSULFONILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS N'-ISOBUTIL-N'-(4-METIL-BENCENOSULFONIL)-HIDRAZIDA DEL ACIDO (2S,4R)-4-MERCAPTO-1-(NAFTALEN-2-SULFONIL)-PIRROLIDIN-2-CARBOXILICO, N'-(4-METIL-BENCENOSULFONIL)-HIDRAZIDA DEL ACIDO (2S,4R)-4-MERCAPTO-1-(NAFTALEN-2-SULFONIL)-PIRROLIDIN-2-CARBOXILICO, N'-BENCIL-HIDRAZIDA DEL ACIDO (2S,4R)-4-MERCAPTO-1-(NAFTALEN-2-SULFONIL)-PIRROLIDIN-2-CARBOXILICO, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. LOS COMPUESTOS MENCIONADOS SON INHIBIDORES DE LAS METALOPROTEASAS Y SON UTILES PARA EL TRATAMIENTO DE ISQUEMIA MIOCARDIACA, ARRITMIA, HIPERTENSION, ASMAREFERS TO COMPOUNDS DERIVED FROM PYRROLIDIN OF FORMULA I WHERE R1 IS H, ALKYLCARBONYL, ARYLCARBONYL; R2 IS RENTAL, ALKYL CYCLOALKYL, ALKYYCLOALKYL ALKYL, CYCLOALKYL, HALOALKYL, AMONG OTHERS; R3 IS H, ARYL, ALKYL, ARYLSULFONYL, AMONG OTHERS; R4 IS H, ARYLALKYL, ALKYL, ARYL, CYCLOALKYL, AMONG OTHERS; R5 IS H, ALKYLSULFONIL, ARYLSULFONIL, HETEROARYLSULFONIL, AMONG OTHERS. PREFERRED COMPOUNDS ARE N'-ISOBUTYL-N '- (4-METHYL-BENZENOSULFONYL) -HYDRAZIDE OF ACID (2S, 4R) -4-MERCAPTO-1- (NAPHTHALEN-2-SULFONIL) -PYRROLIDIN-2-CARBOXYL, N' - (4-METHYL-BENZENOSULFONIL) -HYDRAZIDE OF ACID (2S, 4R) -4-MERCAPTO-1- (NAPHTHALEN-2-SULFONYL) -PYRROLIDIN-2-CARBOXYL, N'-BENZYL-HYDRAZIDE OF ACID (2S, 4R ) -4-MERCAPTO-1- (NAFTALEN-2-SULFONIL) -PIRROLIDIN-2-CARBOXILICO, AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. THE MENTIONED COMPOUNDS ARE INHIBITORS OF METALOPROTEASES AND ARE USEFUL FOR THE TREATMENT OF MYOCARDIAL ISCHEMIA, ARRHYTHMIA, HYPERTENSION, ASTHMA

PE2001000710A 2000-07-19 2001-07-16 PYRROLIDIN DERIVATIVES AS INHIBITORS OF METALOPROTEASES PE20020339A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00114948 2000-07-19

Publications (1)

Publication Number Publication Date
PE20020339A1 true PE20020339A1 (en) 2002-04-23

Family

ID=8169225

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000710A PE20020339A1 (en) 2000-07-19 2001-07-16 PYRROLIDIN DERIVATIVES AS INHIBITORS OF METALOPROTEASES

Country Status (18)

Country Link
US (1) US6444829B1 (en)
EP (1) EP1317428B1 (en)
JP (1) JP2004504298A (en)
KR (1) KR100580056B1 (en)
CN (1) CN1318402C (en)
AR (1) AR033543A1 (en)
AT (1) ATE323673T1 (en)
AU (1) AU2001276396A1 (en)
BR (1) BR0112543A (en)
CA (1) CA2415665A1 (en)
DE (1) DE60118941T2 (en)
ES (1) ES2261443T3 (en)
MX (1) MXPA03000363A (en)
PA (1) PA8522401A1 (en)
PE (1) PE20020339A1 (en)
UY (1) UY26844A1 (en)
WO (1) WO2002006224A1 (en)
ZA (1) ZA200300172B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6589997B2 (en) * 2001-06-29 2003-07-08 North Shore-Long Island Jewish Health System Small-molecule modulators of hepatocyte growth factor/scatter factor activities
CN1294120C (en) * 2003-10-21 2007-01-10 山东大学 Pyrrolidinyl metalloprotease inhibitor and its application
AT509045B1 (en) 2010-01-29 2011-06-15 Planta Naturstoffe Vertriebsges M B H COMPOUNDS FOR THE TREATMENT OF ASTHMA BRONCHIALE
CN103145572A (en) * 2013-03-20 2013-06-12 康化（上海）新药研发有限公司 Asymmetric synthesis method for natural product chlorinated gamma-norvaline hydrochloride
CN105712910B (en) * 2016-03-08 2017-06-06 北京化工大学 （N aryl sulfonyl kias）Sulfohydrazide and preparation method thereof
JP7498179B2 (en) * 2019-08-09 2024-06-11 サンアプロ株式会社 Sulfonamide compound, nonionic photoacid generator, and resin composition for photolithography
CN113030292A (en) * 2021-01-29 2021-06-25 京博农化科技有限公司 Method for analyzing content of p-trifluoromethoxyaniline formylhydrazine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US493333A (en) * 1893-03-14 Air-heating furnace
CA1283906C (en) * 1983-05-09 1991-05-07 Makoto Sunagawa .beta.-LACTAM COMPOUNDS AND PRODUCTION THEREOF
IL117440A0 (en) * 1995-03-31 1996-07-23 Pfizer Pyrrolidinyl hydroxamic acid compounds and their production process
TR199900431T2 (en) * 1996-08-28 1999-04-21 The Procter & Gamble Company �kame edilmi� siklik amin metalloproteaz inhibit�rleri

Also Published As

Publication number Publication date
CN1443163A (en) 2003-09-17
KR100580056B1 (en) 2006-05-12
MXPA03000363A (en) 2003-05-27
UY26844A1 (en) 2002-01-31
PA8522401A1 (en) 2002-09-30
AR033543A1 (en) 2003-12-26
DE60118941T2 (en) 2006-12-21
KR20030024797A (en) 2003-03-26
EP1317428A1 (en) 2003-06-11
CN1318402C (en) 2007-05-30
ATE323673T1 (en) 2006-05-15
BR0112543A (en) 2003-07-01
AU2001276396A1 (en) 2002-01-30
ES2261443T3 (en) 2006-11-16
CA2415665A1 (en) 2002-01-24
US20020040048A1 (en) 2002-04-04
EP1317428B1 (en) 2006-04-19
US6444829B1 (en) 2002-09-03
JP2004504298A (en) 2004-02-12
ZA200300172B (en) 2004-04-07
DE60118941D1 (en) 2006-05-24
WO2002006224A1 (en) 2002-01-24

Similar Documents

Publication Publication Date Title
PE20030062A1 (en) ARALKYLSULFONIL-3- (PYRROL-2-ILMETILIDEN) -2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS
PE20050012A1 (en) BENZOPYRANE COMPOUNDS AS CYCLOOXYGENASE-2 INHIBITORS
PE20011001A1 (en) HETEROCYCLIC COMPOUNDS AS SODIUM / PROTON EXCHANGE INHIBITORS
PE20011314A1 (en) DERIVATIVES OF N- (4-CARBAMIMIDOYL-PHENYL) -GLYCIN AS INHIBITORS OF THE FORMATION OF COAGULATION FACTORS Xa IXa AND THROMBIN
PE20070218A1 (en) AMINO-HYDANTOIN CYCLOALKYL COMPOUNDS AND USE OF THESE FOR THE MODULATION OF ß-SECRETASE
AR054560A1 (en) SPIROPIPERIDINE AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
AR039226A2 (en) USEFUL COMPOUNDS AS PREPARATION INTERMEDIARIES AND PROCEDURES
PE20021089A1 (en) TRIAZOLE COMPOUNDS AS CYTOKINE INHIBITORS
PE20020532A1 (en) NAPHTHALENE DERIVATIVES AS CANABINOID RECEPTOR AGONISTS
PE20010130A1 (en) DERIVATIVES OF 3 (5) -AMINO-PIRAZOLE AND PROCEDURE FOR THEIR PREPARATION
AR037754A1 (en) HERBICIDES
AR036663A1 (en) ESPIRO-HYDANTOINE COMPOUNDS USED AS ANTI-INFLAMMATORY AGENTS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THE INTERMEDIARIES TO PREPARE SUCH COMPOUNDS
AR029216A1 (en) NON-PEPTIDIC INHIBITING COMPOUNDS OF THE VLA-4 DEPENDENT CELL UNION IN THE TREATMENT OF INFLAMMATORY, AUTOIMMUNE AND RESPIRATORY DISEASES; PHARMACEUTICAL COMPOSITION AND TREATMENT PROCEDURE
PE20021006A1 (en) DERIVATIVES OF 3- (4-AMIDOPYRROL-2-ILMETILIDEN) -2-INDOLINONE AS INHIBITORS OF PROTEINQUINASE
PE20080404A1 (en) BENZYL-AMINO-PIPERIDINE DERIVATIVES AS CETP INHIBITORS
EA201170607A1 (en) ACRYLAMID DERIVATIVES APPLICABLE AS INHIBITORS
PE20050525A1 (en) SUBSTITUTED PIRAZOLE DERIVATIVES AND RELATED COMPOUNDS AS ANTAGONISTS OF THE BRADIQUININ B1 RECEPTOR
PE20010696A1 (en) ADENOSINE A3 RECEPTOR AGONIST COMPOUNDS FOR THE TREATMENT OF ISCHEMIA
EA200200708A1 (en) Derivatives of benzene and their use as modulators of JNK
AR041009A1 (en) NITROGEN HETEROCICLICAL COMPOUNDS PRESENTING INHIBITORY ACTIVITY AGAINST HIV INTEGRESS
PE20020338A1 (en) DERIVATIVES OF 3-INDOLYL-4-PHENYL-1H-PYRROL-2,5-DIONA WHICH INHIBIT GLUCOGEN SYNTHASE KINASE-3ß (GSK-3ß)
YU52403A (en) Heterocyclic compounds having antibacterial activity, process for their preparation and pharmaceutical compositions containing them
DE60044432D1 (en) GAMBOGIC ACID DERIVATIVE AS CASPASENACTIVATORS AND APOPTOSIS INDUCTIONS
PE20060589A1 (en) PHENYLAMINOTIZOLES SUBSTITUTED AS ADENOSINE A1 AND A2b AGONISTS
EP1392683A4 (en) CHROMENES SUBTITUES 4 i H / i AND THEIR ANALOGUES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS, AND THEIR USE

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed